Therapy News and Research

RSS

Can Pfizer rescue hormonal replacement therapy?

In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.

16 Nov 2010

Anti-stroke blood thinner shows promise in large clinical trials

In new and extensive clinical trials an experimental blood thinner called rivaroxaban is at least as good at preventing strokes as the drug warfarin – that has been the most widely used agent for the past five decades in people with erratic heartbeats called atrial fibrillations. Researchers said this Monday that this drug also sharply reduces the risk of major bleeding that is seen with warfarin.

16 Nov 2010

Diuretic lessens risk of death from mild heart failure: Study

A new study shows that diuretic pill Inspra (generic – Eplerenone) cuts down the risk of death and hospitalization among people with mild heart failure. The drug that is widely used to treat advanced heart failure, also has value for people with mild disease, says lead researcher Faiez Zannad, of Nancy University in Nancy, France. The results were reported at the American Heart Association's annual meeting and published simultaneously online in the New England Journal of Medicine.

16 Nov 2010

Synexus to develop effective clinical trials for Mild cognitive impairment

Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.

From AES - Accelerated Enrollment Solutions 16 Nov 2010

Medical Acoustics receives UB CAT/NYSTAR grant

Medical Acoustics LLC, a commercial-stage medical device company which employs acoustic technologies for diagnostic and therapeutic medical applications, today announced that it has been awarded a UB CAT/NYSTAR grant.

16 Nov 2010

HUPTI's first group of patients complete prostate cancer treatment

The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.

16 Nov 2010

Dutch government awards Innovation Credit of EUR 1.3 million to InteRNA

InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, today announced that it was awarded an Innovation Credit of EUR 1.3 million from the Dutch government.

16 Nov 2010

New stem cell-infused patch improves heart function after myocardial infarction

University of Cincinnati (UC) researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models.

16 Nov 2010

Study finds two-thirds of asthma patients take combined ICS/LABA treatment

Despite national guidelines recommending that inhaled corticosteroid (ICS) be used alone as the preferred treatment for patients with mild persistent asthma, a new study finds that nearly two-thirds of these patients are taking more costly drugs that combine an ICS and a long-acting beta agonist (LABA) with no apparent additional clinical benefit noted based on pharmacy and medical claims.

16 Nov 2010

BTE Technologies acquires patented recumbent strength-training system, Eccentron

BTE Technologies, a leading global innovator in objective evaluation and rehabilitation equipment for physical therapy, occupational therapy, and sports medicine, announces its acquisition of Eccentron™ - a patented recumbent strength-training system that works the muscles eccentrically for rapid strength gains, explosive muscle power, and unparalleled benefits for joint stability and fall prevention - all with minimal strain on the cardiovascular system.

16 Nov 2010

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

New i-phone application provides instant access to HIV drug interactions

The University of Liverpool has launched an i-phone application, HIV iChart,that provides healthcare professionals and HIV patients with instant and easy access to information about drug interactions.

16 Nov 2010

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association

Targeted Genetics Corporation announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

16 Nov 2010

FDA approves Halaven therapy for metastatic late-stage breast cancer

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD).

16 Nov 2010

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Beth Israel Deaconess Medical Center (BIDMC) will join the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet), a clinical research network sponsored by the National Heart Lung and Blood Institute (NHLBI) to conduct randomized clinical trials to evaluate new and existing medications for the treatment of idiopathic pulmonary fibrosis (IPF). The network is made up of healthcare institutions from around the United States.

16 Nov 2010

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced a total of 11 ZEVALIN related data presentations (five oral, six posters) at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

15 Nov 2010